Leveraging ctDNA as a Prognostic Biomarker in CRC

Postoperative circulating tumor DNA (ctDNA)–based minimal residual disease status demonstrated prognostic value for patients with stage I to IV resected colorectal cancer, showing that those with positive ctDNA after surgery have significantly lower disease-free survival outcomes at 24 months vs those who were ctDNA negative.

Yoshiaki Nakamura, MD, PhD, discusses updated findings from an analysis of the association between circulating tumor DNA minimal residual disease status and disease-free survival in the GALAXY trial, an observational arm of the ongoing CIRCULATE-Japan trial in patients with resected colorectal cancer.